| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | phloretin | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.02 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.02 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |